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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYEmbryonic stem cell-derivedmesenchymal stromal cells (MSCs; also known asmesenchymal stem cells) represent a promising source for
bone regenerative medicine. Despite remarkable advances in stem cell biology, the molecular mechanism regulating differentiation of
human embryonic stem cells (hESCs) into MSCs remains poorly understood. Here, we report that inhibition of IkB kinase (IKK)/nuclear
factor kappa B (NF-kB) signaling enhances differentiation of hESCs into MSCs by expediting the loss of pluripotent markers and
increasing the expression of MSC surface markers. In addition, a significantly higher quantity of MSCs was produced from hESCs
with IKK/NF-kB suppression. These isolated MSCs displayed evident multipotency with capacity to terminally differentiate into osteo-
blasts, chondrocytes, and adipocytes in vitro and to form bone in vivo. Collectively, our data provide important insights into the role
of NF-kB in mesenchymal lineage specification during hESC differentiation, suggesting that IKK inhibitors could be utilized as an adju-
vant in generating MSCs for cell-mediated therapies.INTRODUCTION
Human mesenchymal stromal cells (MSCs; also known as
mesenchymal stem cells) have gained considerable atten-
tion for their promising potential in cell-mediated therapy.
MSCs are progenitor cells whose capacity to differentiate
into osteoblasts andmodulate the immune responsemakes
them instrumental in bone regenerative medicine (Kode
et al., 2009; Stappenbeck and Miyoshi, 2009; Alvarez
et al., 2015; Deng et al., 2015). Clinical trials have already
demonstrated that implantation of MSCs is an effective
and safe treatment modality in defect repair (Bianco
et al., 2013; Quarto et al., 2001; Wang et al., 2012).
Although MSCs used in cell therapies are mostly isolated
from adult bone marrow, proliferation and differentiation
capacity of these MSCs from bone marrow (BMSCs) has
been shown to decline as the donor patient ages (Kern
et al., 2006; Quarto et al., 2001). Due to these shortcomings
of BMSCs, human embryonic stem cells (hESCs), which
have the potential to provide an unlimited supply of
MSCs, are potential alternative sources for MSCs (Choo
and Lim, 2011; Thomson, 1998). hESC-derived MSCs are
similar to BMSCs biologically and functionally, but with
higher osteogenic potential and proliferation rates as well
as less immunogenicity (Li et al., 2013). Three methods
have been developed to promote the differentiation of
hESCs into MSCs: (1) the formation of three-dimensional
embryonic bodies, (2) the culture of hESCs on stromal cells,
and (3) the culture of hESCs as monolayers (Arpornmaek-456 Stem Cell Reports j Vol. 6 j 456–465 j April 12, 2016 j ª2016 The Autholong et al., 2009; Barberi et al., 2005; Villa-Diaz et al.,
2012; Karp et al., 2006). However, the molecular mecha-
nism by which hESCs commit toMSC fate remains elusive.
The nuclear factor kappa B (NF-kB) is known for its key
role in the regulation of many cellular processes. The clas-
sical NF-kB is a heterodimer of p50 and p65/RelA proteins,
in which the p65/RelA subunit has transactivation activity.
The IkB kinase (IKK) complex mediates the degradation of
IkBs to activate NF-kB (Krum et al., 2010). Recent studies
have suggested that NF-kB may also play a role in stem
cell self-renewal and differentiation (Armstrong et al.,
2006; Dreesen and Brivanlou, 2007). The NF-kB subunits,
including p65, p50, IkBa, and IkBb, were found to be pre-
sent throughout differentiation of hESCs (Yang et al.,
2010). Although NF-kB signaling activity is low in hESCs,
its inhibition leads to significant cell differentiation
(Armstrong et al., 2006), suggesting that basal level of
NF-kB activity is required for hESC identity. On the other
hand, p65 overexpression caused loss of pluripotency and
hESC differentiation (Luningschror et al., 2012). Moreover,
it has been shown that Nanog maintains the pluripotency
ofmouse ESCs by binding to and suppressing the functions
of NF-kB transcriptional activity (Torres and Watt, 2008).
Given these seemingly contradictory reports, the precise
regulatory functions of NF-kB in hESC differentiation
require further investigation.
In this report, we investigated the effect of IKK/NF-kB
signaling in regulating differentiation of hESCs into
MSCs. Here, we demonstrated that inactivation of thers
Figure 1. Spontaneous Differentiation of
hESCs without the Feeder Cell Layer
(A) Alkaline phosphatase staining and
quantitative alkaline phosphatase activity
assay at 0, 2, 4, and 7 days. Scale bar in-
dicates 200 mm.
(B) qRT-PCR results of pluripotent markers
(NANOG, OCT4, POU5F1) at 0, 2, 4, and
7 days.
(C) qRT-PCR results of an ectodermal gene
(PAX6), mesodermal genes (PDGFR-a and
BRACHYURY), and an endodermal gene
(FOXA2) at 0, 2, 4, and 7 days.
(D) Flow cytometry analysis of cells ex-
pressing MSC surface markers.
(E) Four-color flow cytometry analysis for
CD45, CD90, CD73, and CD146 expression
was used to isolate CD73+CD90+CD146+
CD45 MSCs.
(F) Western blot of p65 and phosphorylated
p65 at 0, 2, 4, and 7 days of hESC differen-
tiation.
(G) Western blot of IkBa and phosphory-
lated IkBa at 0, 2, 4, and 7 days of H1 hESC
differentiation. Three independent experi-
ments were performed.
*p < 0.05, **p < 0.001.IKK/NF-kB signaling pathway by the small-molecule IKK
inhibitor (IKKi) and p65 knockdown promotes hESC differ-
entiation into MSCs on monolayer culture. IKKi-treated
hESCs generated a significantly increased MSC population
and exhibited multipotency.RESULTS
Inhibition of NF-kB Signaling Promotes hESC
Differentiation and Enhances MSCMarker Expression
hESCs can be differentiated into MSCs when they are
cultured in a monolayer without feeder cells (Karp et al.,
2006). To induce this differentiation, we seeded the H1
hESC aggregates onto tissue culture dishes without feeder
cells. We found that the alkaline phosphatase activity of
hESCs decreased progressively and dramatically in the
7 days following culturing in a monolayer (Figure 1A).
Real-time RT-PCR revealed that the expression of pluripo-Stemtent markers, including NANOG, OCT4, and SOX2, gradu-
ally declined in parallel with alkaline phosphatase activity,
indicating hESC differentiation (Figure 1B).
We then examined the expression pattern of markers
indicative of the three germ layers. While the ectodermal
marker gene PAX6 was not induced, the endodermal
marker gene FOXA2 and two mesodermal markers
PDGFR-a and BRACHYURY were significantly elevated
upon monolayer culture, indicating their preferential dif-
ferentiation toward these two specific lineages (Figure 1C).
Furthermore, when the MSC surface markers were as-
sessed after 7 days of differentiation, more than 95% of
cells were positive for CD51 and CD90, but negative for
CD34 and CD45 (Figure 1D). However, CD146+ cells
were 74.2% and CD73+ cells were relatively low at 4.9%
(Figure 1D). Based on these results, we selected the combi-
nation markers of CD73+CD90+CD146+CD45 to isolate
MSCs, excluding CD51 due to its high level of expres-
sion at 99% (Figure 1D). We were able to obtain 3.6%Cell Reports j Vol. 6 j 456–465 j April 12, 2016 j ª2016 The Authors 457
CD73+CD90+CD146+CD45 MSCs of the total differ-
entiated cells from H1 hESCs (Figure 1E). Similarly,
MSCs could also be generated from H9 hESCs (Figures
S1A–S1E).
IKK directly phosphorylates the p65 transactivation
domain on serine 536 (S536), a process that is correlated
with IKK/NF-kB activity (Yang et al., 2003). To examine
the status of the IKK/NF-kB signaling pathway, we screened
for phosphorylated p65 during hESC differentiation.
Consistent with previous studies (Foldes et al., 2010;
Kang et al., 2007), phosphorylated status of p65 and IkBa
was low, suggesting that NF-kB activity is present but low
in H1 hESCs (Figures 1F and 1G). Interestingly, phosphor-
ylation of p65 and IkBa increased progressively in the first
4 days of H1 or H9 hESC differentiation, but decreased to
the basal level on day 7 (Figures 1F, 1G, and S1F). In
contrast, the components of non-canonical NF-kB
signaling, p100 and p52 (Bakkar et al., 2012), were mini-
mally affected (Figure S1G).
To determine whether IKK/NF-kB signaling plays a func-
tional role in hESC differentiation intoMSCs, we used IKKi
to inhibit the IKKb subunit of IKK complex, blocking IKK-
mediated phosphorylation-induced proteasomal degrada-
tion of IkB, and thereby disabling activation of NF-kB
(Baxter et al., 2004; Park et al., 2006). We treated the H1
hESC monolayer culture daily with IKKi (1 mM) from day
1 to day 4 during which IKK/NF-kB activity was found to
be upregulated. This treatment resulted in significant inhi-
bition of p65 and IkBa phosphorylation (Figures 2A and
2B), as well as reduction in alkaline phosphatase activity
(Figure 2C) compared with vehicle control at days 2 and
4 of H1 hESC differentiation. Similarly, during the 7-day
differentiation period, IKKi treatment consistently expe-
dited the loss of pluripotency in H1 hESCs as determined
by further suppressed mRNA expression levels of pluripo-
tent markers, including NANOG, OCT4, and SOX2 (Fig-
ure 2D). Germ layer marker examination revealed that
mesodermal markers PDGFR-a and BRACHYURY were
found to be significantly upregulated as a result of treat-
ment at days 2 and 4 of hESC differentiation (Figure 2E).
The endodermal marker FOXA2 was also upregulated at
day 4 (Figure 2E). In contrast, the ectodermal marker
PAX6 gene expression remained unchanged (Figure 2E).
MSC marker assessment showed that CD73 and CD146
were significantly upregulated following 4 days of IKKi
treatment (Figure 2F); such upregulation was further
confirmed by flow cytometry analysis (Figure 2G). IKKi
treatment also generated a 3-fold increase in the propor-
tion of CD73+CD90+CD146+CD45 MSCs in the total
differentiated H1 hESC population, compared with vehicle
control treatment (Figure 2H). Similarly, we found that
IKKi treatment also significantly generated more MSCs
from H9 hESCs (Figure S2).458 Stem Cell Reports j Vol. 6 j 456–465 j April 12, 2016 j ª2016 The AuthoIKKi-Treated Cells Exhibit Enhanced Osteogenic and
Chondrogenic Potentials
As IKKi treatment during hESC differentiation generated a
larger CD73+CD90+CD146+CD45 MSC population, we
examined whether inhibiting NF-kB signaling by IKKi en-
hances terminal differentiation capacity of differentiated
hESCs. After H1 hESCs were grown in monolayer culture
for 7 days with and without IKKi, these differentiated and
unsorted hESCs were further induced to undergo osteo-
genic differentiation with osteogenic induction (OI) me-
dium in the absence of IKKi for 7 days. As shown in Fig-
ure S3A, alkaline phosphatase activity was significantly
elevated in IKKi-pretreated cells compared with control
cells. In addition, real-time RT-PCR showed elevated
expression levels of osteogenic markers, including RUNX2
and BGLAP (Figure S3B). Consistent with 7-day osteogenic
induction results, IKKi-pretreated cells were able to form
more mineralized nodules than control cells after pro-
longed treatment with OI medium for 14 days as demon-
strated by Alizarin red staining (Figure S3C).
Furthermore, we evaluated and compared the chondro-
genic capacity of differentiated H1 hESCs under chondro-
genic conditions. IKKi-pretreated cells showed the pres-
ence of increased glycosaminoglycans as demonstrated by
Alcian blue staining following prolonged treatment with
chondrogenic induction medium for 21 days (Figure S3D).
mRNA expression levels of chondrogenic marker genes
including SOX9 and COL2A1 were also significantly upre-
gulated (Figure S3E).
Inhibition of NF-kB Signaling by p65 Depletion
Promotes hESC Differentiation and Enhances MSC
Marker Expression
To further confirm that inhibition of NF-kB promotes hESC
differentiation, we knocked down p65 in hESCs using
lentiviruses expressing p65 small hairpin RNAs (shRNAs),
targeting the 30 UTR. The depletion of p65 in H1 hESCs
was confirmed by real-time RT-PCR (Figure 3A) and by
significantly suppressed expression of NF-kB target genes,
including cIAP2, IL-6, and IL-8 (Figure 3B). Consistent
with our IKKi treatment results, this p65 deficiency showed
the decline of alkaline phosphatase activity at days 2 and 4
of the differentiation process (Figure 3C). Moreover, real-
time RT-PCR revealed accelerated loss of the pluripotent
markers NANOG, OCT4, and SOX2 during hESC differenti-
ation (Figure 3D). As with IKKi treatment, the endodermal
marker FOXA2 and two mesodermal markers PDGFR-a and
BRACHYURY were found to be significantly elevated while
the ectodermal marker PAX6 was unchanged (Figure 3E).
The expression of CD73 and CD146 was also significantly
upregulated in a time-dependent manner, with the most
drastic differences at day 7 of hESC differentiation (Fig-
ure 3F). Flow cytometry analysis confirmed the increasedrs
Figure 2. Effect of IKKi Treatment on Mesenchymal Lineage Specification of hESCs
(A) Western blot of p65 and phosphorylated p65 at 0, 2, and 4 days of hESC differentiation.
(B) Western blot of IkBa and phosphorylated IkBa at 0, 2, and 4 days of hESC differentiation.
(C) Alkaline phosphatase staining and quantitative alkaline phosphatase activity assay at 2 and 4 days. Scale bar indicates 200 mm.
(legend continued on next page)
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expression of CD73 andCD146 (Figure 3G). Finally, similar
to IKKi treatment, NF-kB inhibition by p65 depletion
increased the proportion of CD73+CD90+CD146+CD45
MSCs by 3-fold (Figure 3H).MSCs Derived from IKKi-Treated hESCs Maintain
Multipotency In Vitro and Form Bone In Vivo
Since IKKi treatment generated significantly more MSCs
from hESCs, it was important to determine whether these
MSCs maintained multipotential properties and formed
bone tissues in vivo. We sorted MSCs derived from IKKi-
treated H1 hESCs and vehicle-treated hESCs and compared
the terminal differentiation capacity to develop into osteo-
blasts, chondrocytes, and adipocytes in the absence of IKKi.
Induced to undergo osteogenic differentiation, both groups
displayed similar alkaline phosphatase activity and miner-
alization capacity (Figures 4A and 4C). Real-time RT-PCR
also showed no significant differences in the expression
of the osteogenic marker genes, RUNX2 and BGLAP (Fig-
ure 4B). Similarly, no significant changes were observed in
chondrogenicpotential, asdeterminedbyAlcianblue stain-
ing and expression of the chondrogenic marker genes,
SOX9 andCOL2A1 (Figures 4D and4E). Induced to undergo
adipogenic differentiation with adipogenic induction me-
dia for 21 days, oil red O staining revealed lipid deposit for-
mation (Figure 4F) and the quantification and expression of
adipogenic marker genes, PPAR-g and LPL, showed no dif-
ference in adipogenic potential between the two groups
(Figures 4F and 4G). Importantly, both populations were
able to form bone in vivo (Figure 4H). To confirm ectopic
bone regeneration, we examined the expression of human
osteocalcin in thesemineralized tissues.Osteocytes and lin-
ing osteoblasts were positively stained in both groups (Fig-
ure S4). To examine whether IKKi treatment might induce
chromosomal abnormality at the genomic level, we per-
formed G-banded chromosome studies of 20 mitoses. The
results revealed that both groups exhibited a normal male
karyotype with no gross abnormalities (Figure 4I).DISCUSSION
For successful utilization of hESCs to generate MSCs for
cell-mediated therapies, it is critical to develop a better un-(D) qRT-PCR results of NANOG, OCT4, and POU5F1 at 2 and 4 days.
(E) qRT-PCR results of PAX6, PDGFR-a, BRACHYURY, and FOXA2 at 2 an
(F) qRT-PCR results of CD73 and CD146 at 2, 4, and 7 days.
(G) Flow cytometry analysis of cells with or without IKKi treatment e
(H) Four-color flow cytometry analysis for CD45, CD90, CD73, and CD
7 days of hESC differentiation with or without IKKi. Proportions
experiments were performed.
*p < 0.05, **p < 0.001.
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their differentiation into specific progenitor cells. Here,
we identified an important mechanism that facilitates dif-
ferentiation of pluripotent hESCs into multipotent MSCs.
By inhibiting the NF-kB signaling pathway, hESCs were
differentiated more readily into MSCs, thereby enhancing
lineage-specific terminal differentiation into osteoblasts
and chondrocytes.
Recent studies have suggested that NF-kB signaling
is involved in both maintenance and differentiation of
ESCs (Dreesen and Brivanlou, 2007). While a low but
detectable level of NF-kB activity was found in both mouse
ESCs (mESCs) and hESCs (Torres and Watt, 2008; Yang
et al., 2010), the functional role of NF-kB signaling was
found to be contradictory. In mESCs, endogenous NF-kB
activity and target gene expression was observed to have
increased during the differentiation process. In addition,
forced expression of the NF-kB subunit p65 caused mESC
differentiation and loss of pluripotency (Luningschror
et al., 2012). Conversely, NF-kB inhibition in mice in-
creases expression of pluripotency markers (Dutta et al.,
2011). miR-290, an ESC-specific microRNA cluster that tar-
gets p65, maintains pluripotency in mESCs by repressing
NF-kB signaling (Luningschror et al., 2012). Similarly,
Nanog’s binding to NF-kB inhibits the transcriptional
activity of NF-kB and collaborates with Stat3 to promote
self-renewal and impair differentiation (Torres and Watt,
2008). In contrast, it is reported that NF-kB inhibition in
hESCs leads to hESC differentiation and loss of pluripo-
tency (Armstrong et al., 2006). Using two different ap-
proaches for inhibiting NF-kB, our findings confirmed the
notion that NF-kB inhibition promoted hESC differentia-
tion. Importantly, we found that inhibition obtained
significantly higher yields of MSCs. It was reported that
there was a significant increase in expression of the NF-kB
pathway components, p50 and phosphorylated form of
p65, during embryonic body-mediated differentiation of
hESCs grown in mouse embryonic feeder (MEF) layers
(Yang et al., 2010). Similarly, here we demonstrated an in-
crease in phosphorylated p65, indicative of heightened
IKK/NF-kB activity, as hESCs differentiated in the mono-
layer culturing system and lost their pluripotency. It is
noteworthy that such heightened activity was present
only during the initial 4 days of differentiation and quicklyd 4 days.
xamining MSC marker expression.
146 expression to isolate CD73+CD90+CD146+CD45 MSCs following
of CD73+CD90+CD146+CD45 MSCs generated. Three independent
rs
Figure 3. Effect of p65 Knockdown on Differentiation and Mesenchymal Lineage Specification of hESCs
(A) qRT-PCR showing the deletion of p65 mRNA by shp65 in H1 hESCs.
(B) qRT-PCR results of NF-kB target genes (cIAP2, IL-6, IL-8) in Scr or shp65 transduced H1 hESCs at 4 days.
(legend continued on next page)
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returned to the basal level. When this transient upregula-
tion of IKK/NF-kB signaling was inhibited, hESC differenti-
ation was enhanced, suggesting that IKK/NF-kB activity
may act as a compensatory mechanism to suppress its dif-
ferentiation into progenitor cells during the early stages.
Indeed, such a compensatory mechanism was also seen
in previous studies. NF-kB activity is high during the devel-
opment of bone but decreases in adult bone (Krum et al.,
2010). Previously, we have found that the inhibition of
NF-kB signaling promotes osteogenic differentiation of
MSCs in vivo and in vitro (Chang et al., 2009, 2013). Alto-
gether, our results suggest that NF-kB is a negative regulator
of MSC differentiation from ESCs and bone formation.
It has previously been reported that differentiation of
hESCs without the embryonic body stage led to an increase
in the capacity of hESCs to differentiate into osteogenic
progenitor cells (Karp et al., 2006). Consistent with these
findings, our differentiation culture method resulted in
cells with increased mesodermal and endodermal lineage
marker gene expression, while the expression of the ecto-
dermal lineage marker, PAX6, was unchanged. These re-
sults differ distinctly from embryonic bodies in which the
inhibition of NF-kB promotes ectodermal lineage alone.
Such discrepancies may stem from differences in culturing
conditions including dosing. Yang et al. (2010) used a
20 mM dose of IKKi daily for 6 days, which is significantly
higher than the concentration used in this study, 1 mM.
This super-physiological concentration of IKKi may be
responsible for the significant cell death and morphology
changes that Yang et al. (2010) observed in hESCs. During
our dosing optimization studies, we initially experienced
massive cell death with higher doses, leading us to decide
on a 1 mM dose. While IKKi at this low dose not only in-
duces minimal cell death and proliferation impairment,
it is sufficient to significantly suppress IKK activity, as
demonstrated by a reduction in the S536 phosphorylated
form of p65. As such, evaluating the role of NF-kB signaling
by directly comparing different culturing conditions war-
rants closer examination.
In summary, we demonstrated that hESCs are a reliable
resource to generate functional MSCs, making hESC-
derived MSCs a promising alternative to BMSCs, which
require invasive harvesting and show diminishing differ-(C) Alkaline phosphatase staining and quantitative alkaline phospha
lentivirus at 2 and 4 days. Scale bar indicates 200 mm.
(D) qRT-PCR results of NANOG, OCT4, and POU5F1 at 2 and 4 days.
(E) qRT-PCR results of PAX6, PDGFR-a, BRACHYURY, and FOXA2 at 2 an
(F) qRT-PCR results of CD73 and CD146 at 2, 4, and 7 days.
(G) Flow cytometry analysis of cells expressing MSC markers.
(H) Four-color flow cytometry analysis for CD45, CD90, CD73, and CD1
hESC differentiation. Three independent experiments were performed
*p < 0.05, **p < 0.001.
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that inhibition of NF-kB signaling promotes differentiation
of hESCs into MSCs. By inhibiting IKK/NF-kB signaling,
greater quantities ofMSCs can be obtainedmore efficiently.
Purified MSCs generated with IKKi treatment had the ca-
pacity for in vivo bone formation, offering tremendous
benefits for bone tissue engineering. Therefore, the use of
IKKi to inhibit NF-kB signaling to derive and enrich
functional MSCs from hESCs may represent an efficient
method that holds great promise for regenerative medicine
in the future.EXPERIMENTAL PROCEDURES
Cell Culture
hESC-related work was approved by UCLA Embryonic Stem Cells
Research Oversight Committee (IRB: 10-001711-CR-00001). H1
andH9 hESCs were obtained fromUCLA Broad StemCell Research
Center. hESCs (passages 35–45) were cultured on a mitotically in-
activated MEF layer, as previously described (Thomson, 1998). To
induce differentiation of hESCs, we detached hESC colonies using
type IV collagenase (1 mg/ml), and hESC aggregates were plated
into tissue culture dishes and grown in DMEM, containing 15%
fetal bovine serum, 1% L-glutamine, 1% non-essential amino
acid, and 1% penicillin-streptomycin for 1 day. Subsequently,
IKKi (1 mM, Calbiochem) was added during ESC differentiation
as indicated. After 7 days of differentiation, the derived cells
were trypsinized to generate a single-cell suspension for further
differentiation.
shRNA Knockdown
To knockdown p65 during differentiation of hESCs, we packaged
and generated the lentiviruses expressing shRNA p65 or scramble
shRNA (Scr) in 293T cells as described previously (Ramadoss
et al., 2011). For viral infection, ESC aggregates were plated over-
night and then infected with lentiviruses in the presence of poly-
brene (6 mg/ml) for 24 hr. After 3 days of infection, pools of colonies
were selected with puromycin (Thermo Fisher Scientific) for 3 days
at a concentration of 0.4 mg/ml. The target sequence for p65 shRNA
was 50-GTGACAAGGTGCAGAAAGA-30.
All procedures were performed in accordance with the approved
protocol by the University of California, Los Angeles (UCLA),
and were oversight by UCLA Animal Research Committee (ARC).
Detailed procedures are listed in Supplemental Experimental
Procedures.tase activity assay for hESCs after transfection with Scr or shp65
d 4 days.
46 to isolate CD73+CD90+CD146+CD45 MSCs following 7 days of H1
.
rs
Figure 4. Characterization of Sorted MSCs Derived from IKKi-Treated hESCs
(A) Alkaline phosphatase staining and quantitative alkaline phosphatase activity assay after 14 days of osteogenic induction (OI).
(B) qRT-PCR results of osteogenic markers (RUNX2 and BGLAP) after 7 days of OI.
(C) ARS staining and quantification after 14 days of OI.
(D) Alcian blue staining and quantification after 21 days of chondrogenic induction.
(E) qRT-PCR results of chondrogenic markers (SOX9 and COL2a1) expression after 14 days of chondrogenic induction (CI).
(F) Oil red O staining and quantification after 21 days of adipogenic induction (AI). Scale bar indicates 200 mm.
(G) qRT-PCR results of adipogenic markers (PPAR-g and LPL) expression after 14 days of AI.
(H) Bone formation in vivo by sorted MSCs derived from IKKi-treated H1 hESCs in six immunocompromised mice. Bar indicates 100 mm.
(I) Karyotype analysis of sorted MSCs derived from IKKi-treated H1 hESCs. For all in vitro experiments, three independent experiments were
performed.
Stem Cell Reports j Vol. 6 j 456–465 j April 12, 2016 j ª2016 The Authors 463
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and one table and can be found with this
article online at http://dx.doi.org/10.1016/j.stemcr.2016.02.006.
AUTHOR CONTRIBUTIONS
D.P., C.Z., and R.A. performed the experiments and analyzed
the data. C.H. and C.Y.W. designed experiments and wrote the
manuscript.
ACKNOWLEDGMENTS
Thisworkwas supportedby theUCLAEli & Edythe BroadCenter of
Regenerative Medicine and Stem Cell Research Innovation Award
and NIH/NIDCR grant R01DE016513. We thank Dr. Jinghua Tang
for technical support on cell culture.
Received: October 29, 2015
Revised: February 5, 2016
Accepted: February 8, 2016
Published: March 10, 2016REFERENCES
Alvarez, R., Lee, H.L., Wang, C.Y., and Hong, C. (2015). Character-
ization of the osteogenic potential ofmesenchymal stem cells from
human periodontal ligament based on cell surface markers. Int. J.
Oral Sci. 7, 213–219.
Armstrong, L., Hughes, O., Yung, S., Hyslop, L., Stewart, R., Wap-
pler, I., Peters, H., Walter, T., Stojkovic, P., Evans, J., et al. (2006).
The role of PI3K/AKT, MAPK/ERK and NFkappabeta signalling in
the maintenance of human embryonic stem cell pluripotency
and viability highlighted by transcriptional profiling and func-
tional analysis. Hum. Mol. Genet. 15, 1894–1913.
Arpornmaeklong, P., Brown, S.E., Wang, Z., and Krebsbach, P.H.
(2009). Phenotypic characterization, osteoblastic differentiation,
and bone regeneration capacity of human embryonic stem cell-
derived mesenchymal stem cells. Stem Cells Dev. 18, 955–968.
Bakkar, N., Ladner, K., Canan, B.D., Liyanarachchi, S., Bal, N.C.,
Pant, M., Periasamy, M., Li, Q., Janssen, P.M., and Guttridge,
D.C. (2012). IKKa and alternative NF-kB regulate PGC-1b to pro-
mote oxidative muscle metabolism. J. Cell Biol. 196, 497–511.
Barberi, T., Willis, L.M., Socci, N.D., and Studer, L. (2005). Deriva-
tion of multipotent mesenchymal precursors from human embry-
onic stem cells. PLoS Med. 2, e161.
Baxter, A., Brough, S., Cooper, A., Floettmann, E., Foster, S.,
Harding, C., Kettle, J., McInally, T., Martin, C., Mobbs, M., et al.
(2004). Hit-to-lead studies: the discovery of potent, orally active,
thiophene carboxamide IKK-2 inhibitors. Bioorg. Med. Chem.
Lett. 14, 2817–2822.
Bianco, P., Cao, X., Frenett, P.S., Mao, J.J., Robey, P.G., Simmons,
P.J., andWang, C.Y. (2013). Themeaning, the sense and the signif-
icance: translating the science of mesenchymal stem cells into
medicine. Nat. Med. 19, 35–42.
Chang, J., Wang, Z., Tang, E., Fan, Z., McCauley, L., Franceschi, R.,
Guan, K., Krebsbach, P.H., and Wang, C.Y. (2009). Inhibition of464 Stem Cell Reports j Vol. 6 j 456–465 j April 12, 2016 j ª2016 The Authoosteoblastic bone formation by nuclear factor-kappaB. Nat. Med.
15, 682–689.
Chang, J., Liu, F., Lee,M.,Wu, B., Ting, K., Zara, J.N., Soo, C., Al He-
zaimi, K., Zou, W., Chen, X., et al. (2013). NF-kB inhibits osteo-
genic differentiation of mesenchymal stem cells by promoting
b-catenin degradation. Proc. Natl. Acad. Sci. USA 110, 9469–9474.
Choo, A., and Lim, S.K. (2011). Derivation of mesenchymal stem
cells from human embryonic stem cells. Methods Mol. Biol. 690,
175–182.
Deng, P., Chen, Q.M., Hong, C., and Wang, C.Y. (2015). Histone
methyltransferases and demethylases: regulators in balancing
osteogenic and adipogenic differentiation of mesenchymal stem
cells. Int. J. Oral Sci. 7, 197–204.
Dreesen, O., and Brivanlou, A.H. (2007). Signaling pathways in
cancer and embryonic stem cells. Stem Cell Rev. 3, 7–17.
Dutta, D., Ray, S., Home, P., Larson, M., Wolfe, M.W., and Paul, S.
(2011). Self-renewal versus lineage commitment of embryonic
stem cells: protein kinase C signaling shifts the balance. StemCells
4, 618–628.
Foldes, G., Liu, A., Badiger, R., Paul-Clark, M., Moreno, L., Lendvai,
Z., Wright, J.S., Ali, N.N., Harding, S.E., and Mitchell, J.A. (2010).
Innate immunity in human embryonic stem cells: comparison
with adult human endothelial cells. PLoS One 5, e10501.
Kang, H.B., Kim, Y.E., Kwon, H.J., Sok, D.E., and Lee, Y. (2007).
Enhancement ofNF-kappaB expression and activity upondifferen-
tiation of human embryonic stem cell line SNUhES3. Stem Cells
Dev. 16, 615–623.
Karp, J.M., Ferreira, L.S., Khademhosseini, A., Kwon, A.H., Yeh, J.,
and Langer, R.S. (2006). Cultivation of human embryonic stem
cells without the embryoid body step enhances osteogenesis
in vitro. Stem Cells 24, 835–843.
Kern, S., Eichler, H., Stoeve, J., Kluter, H., and Bieback, K. (2006).
Comparative analysis of mesenchymal stem cells from bone
marrow, umbilical cord blood, or adipose tissue. Stem Cells 24,
1294–1301.
Kode, J.A., Mukherjee, S., Joglekar, M.V., andHardikar, A.A. (2009).
Mesenchymal stem cells: immunobiology and role in immunomo-
dulation and tissue regeneration. Cytotherapy 11, 377–391.
Krum, S.A., Chang, J., Miranda-Carboni, G., and Wang, C.-Y.
(2010). Novel functions for NFkB: inhibition of bone formation.
Nat. Rev. Rheumatol. 6, 607–611.
Li, O., Tormin, A., Sundberg, B., Hyllner, J., Le Blanc, K., and Sched-
ing, S. (2013). Human embryonic stem cell-derived mesenchymal
stroma cells (hES-MSCs) engraft in vivo and support hematopoiesis
without suppressing immune function: implications for off-the
shelf ES-MSC therapies. PLoS One 8, e55319.
Luningschror, P., Stocker, B., Kaltschmidt, B., and Kaltschmidt, C.
(2012). miR-290 cluster modulates pluripotency by repressing
canonical NF-kappaB signaling. Stem Cells 30, 655–664.
Park, B.K., Zhang,H., Zeng,Q., Dai, J., Keller, E.T., Giordano, T., Gu,
K., Shah, V., Pei, L., Zarbo, R.J., et al. (2006). NF-kB in breast cancer
cells promotes osteolytic bone metastasis by inducing osteoclasto-
genesis via GM-CSF. Nat. Med. 13, 62–69.
Quarto, R., Mastrogiacomo, M., Cancedda, R., Kutepov, S.M.,
Mukhachev, V., Lavroukov, A., Kon, E., and Marcacci, M. (2001).rs
Repair of large bone defects with the use of autologous bone
marrow stromal cells. N. Engl. J. Med. 344, 385–386.
Ramadoss, S., Li, J., Ding,X., Al Hezaimi, K., andWang,C.Y. (2011).
Transducin beta-like protein 1 recruits nuclear factor kappaB to the
target gene promoter for transcriptional activation. Mol. Cell. Biol.
31, 924–934.
Stappenbeck, T.S., andMiyoshi, H. (2009). The role of stromal stem
cells in tissue regeneration and wound repair. Science 324, 1666–
1669.
Thomson, J.A. (1998). Embryonic stem cell lines derived from hu-
man blastocysts. Science 282, 1145–1147.
Torres, J., andWatt, F.M. (2008). Nanog maintains pluripotency of
mouse embryonic stem cells by inhibiting NFkappaB and cooper-
ating with Stat3. Nat. Cell Biol. 10, 194–201.StemVilla-Diaz, L., Brown, S., Liu, Y., Ross, A., Lahann, J., Parent, J., and
Krebsbach, P. (2012). Derivation of mesenchymal stem cells from
human induced pluripotent stem cells cultured on synthetic sub-
strates. Stem Cells 30, 1174–1181.
Wang, S., Qu, X., and Zhao, R.C. (2012). Clinical applications of
mesenchymal stem cells. J Hematol. Oncol. 5, 19.
Yang, F., Tang, E., Guan, K., andWang, C.-Y. (2003). IKKb plays an
essential role in the phosphorylation of RelA/p65 on serine 536
induced by lipopolysaccharide. J. Immunol. 170, 5630–5635.
Yang, C., Atkinson, S.P., Vilella, F., Lloret,M., Armstrong, L., Mann,
D.A., and Lako, M. (2010). Opposing putative roles for canonical
and noncanonical NFkappaB signaling on the survival, prolifera-
tion, and differentiation potential of human embryonic stem cells.
Stem Cells 28, 1970–1980.Cell Reports j Vol. 6 j 456–465 j April 12, 2016 j ª2016 The Authors 465
